ArticlesComparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial
Introduction
Rheumatoid arthritis is a chronic inflammatory disease with varying course.1 Despite the best therapeutic efforts, in a great number of cases the disease shows a resistant course with progressive joint destruction and physical disability.2, 3, 4, 5, 6, 7
There is increasing evidence from randomised clinical trials and longitudinal observational studies that conventional single-drug therapy with disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids can alter the clinical course of rheumatoid arthritis, but in most patients the benefits are insufficient.7, 8, 9, 10, 11, 12, 13, 14 Therefore, more powerful therapies are needed, such as the use of more than one DMARD simultaneously in the hope of additive efficacy.15 Most clinical trials using various combination therapies have not, however, shown increased efficacy.16, 17 In two short-term controlled clinical trials of patients with advanced disease, the combinaton of DMARDs seemed to improve the outcome for patients in comparison with single-drug treatment.18, 19 By contrast, in two randomised combination studies of patients with very early rheumatoid arthritis, neither a combination of high-dose prednisolone (for 28 weeks), methotrexate (for 40 weeks), and sulphasalazine, nor methotrexate with sulphasalazine, showed any benefit on disease activity over single-drug treatment at 1 year.20, 21
In our study we compared the efficacy and tolerability of a DMARD combination including sulphasalazine, methotrexate, hydroxychloroquine, and low-dose prednisolone with the same DMARDs as single treatment with or without oral prednisolone in patients with early, active rheumatoid arthritis. The primary aim of both the treatment regimens was the induction of remission. As other endpoints we used the number of patients achieving clinical improvement (American College of Rheumatology [ACR] criteria of 50% clinical response), and the extent of radiological joint damage.
Section snippets
Patients
Patients were recruited between April, 1993, and May, 1995. Inclusion requirements were: the criteria of the American Rheumatism Association for rheumatoid arthritis;22 age between 18 and 65 years; duration of symptoms of less than 2 years; active disease with three or more swollen joints and at least three of the following: erythrocyte sedimentation rate (ESR), at least 28 mm/h or C-reactive protein (CRP) concentration above 19 mg/L; morning stiffness of 29 min or more; more than five swollen
Results
The 199 eligible patients were randomised (figure 1). There were no substantial differences between the groups in baseline characteristics of patients (table 1).
87 (90%) combination-group and 91 (93%) single-treatment-group patients completed the treatment according to the protocol. No patient discontinued the study because of toxic effects of drugs, but one did so because of lack of efficacy (figure 1).
At the end of the study, 36 (37%) and 18 (18%), respectively, of the patients originally
Discussion
Most rheumatologists agree that DMARD treatment should be introduced early in the course of rheumatoid arthritis and that the ultimate target of treatment should be the induction of remission.27 More aggressive use of DMARDs, for example, in combination, should be favoured.19 Most previous studies have investigated this issue in patients with advanced disease. In one study of patients with early rheumatoid arthritis, the rapid clinical response and high remission rate disappeared after the
References (31)
- et al.
Long-term outcome of treating rheumatoid arthritis: results after 20 years
Lancet
(1987) Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clincal trials
J Clin Epidemiol
(1988)- et al.
Rheumatoid arthritis: disease-modifying antirheumatic drugs
Clin Rheum Dis
(1983) - et al.
Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up
Lancet
(1990) - et al.
Randomised comparison of combined step-down prednisolone, methotrexate, and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
Lancet
(1997) - et al.
Rheumatoid arthritis clinical features
- et al.
Does drug therapy slow radiographic deterioration in rheumatoid arthritis?
N Engl J Med
(1983) - et al.
Remission in rheumatoid arthritis
J Rheumatol
(1985) 50 years of antirheumatic therapy: the prognosis of rheumatoid arthritis
J Rheumatol
(1990)Rational use of disease-modifying antirheumatic drugs
Drugs
(1990)
Auranofin treatment in early rheumatoid arthritis may postpone early retirement: results from a 2-year double blind trial
J Rheumatol
Sulphasalazine in early rheumatoid arthritis: double blind, 48 week prospective, placebo controlled study
Arthritis Rheum
Second-line drug therapy for rheumatoid arthritis
N Engl J Med
Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis
Lancet
Outcome in patients with early rheumatoid arthritis treated according to “sawtooth” strategy
Arthritis Rheum
Cited by (802)
Rheumatoid arthritis
2023, Medicina ClinicaEditorial Commentary: If Individual Treatments Are Potentiated, Multimodal Therapy Including Cells and Platelet-Rich Plasma May Beneficially Treat Cartilage Degeneration and Arthritis
2021, Arthroscopy - Journal of Arthroscopic and Related SurgeryHydroxychloroquine in systemic and autoimmune diseases: Where are we now?
2021, Revue du Rhumatisme (Edition Francaise)Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?
2021, Joint Bone SpineUnlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy
2024, British Journal of CancerSignificance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer
2024, Experimental and Molecular Medicine
Other members listed at end of paper